Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ipsen S.A.

103.50
0.0000
Volume:- -
Turnover:- -
Market Cap:8.55B
PE:11.85
High:103.50
Open:103.50
Low:103.50
Close:103.50
Loading ...

Company Profile

Company Name:
Ipsen S.A.
Exchange:
PINK LIMITED
Establishment Date:
1929
Employees:
5358
Office Location:
65, quai Georges Gorse,Boulogne-Billancourt,Ile-de-France,France
Zip Code:
92100
Fax:
33 1 58 33 50 01
Introduction:
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.